Figure 4. Total consumption (DDD/1,000 inhabitant-days) by quarter of oral macrolides (J01FA) dispensed by retail pharmacies in Canada, 2000–2009
| Quarter and Year |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
| Antimicrobial |
Q1 |
Q2 |
Q3 |
Q4 |
Q1 |
Q2 |
Q3 |
Q4 |
Q1 |
Q2 |
Q3 |
Q4 |
Q1 |
Q2 |
Q3 |
Q4 |
Q1 |
Q2 |
Q3 |
Q4 |
Q1 |
Q2 |
Q3 |
Q4 |
Q1 |
Q2 |
Q3 |
Q4 |
Q1 |
Q2 |
Q3 |
Q4 |
Q1 |
Q2 |
Q3 |
Q4 |
Q1 |
Q2 |
Q3 |
Q4 |
| Erythromycin (J01FA01) |
1.06 |
0.88 |
0.71 |
0.88 |
0.94 |
0.70 |
0.54 |
0.68 |
0.69 |
0.55 |
0.48 |
0.57 |
0.58 |
0.51 |
0.44 |
0.54 |
0.50 |
0.43 |
0.37 |
0.41 |
0.43 |
0.36 |
0.30 |
0.35 |
0.38 |
0.32 |
0.27 |
0.31 |
0.33 |
0.28 |
0.24 |
0.26 |
0.29 |
0.26 |
0.22 |
0.24 |
0.24 |
0.22 |
0.19 |
0.20 |
| Clarithromycin (J01FA09) |
2.67 |
1.99 |
1.60 |
2.58 |
3.11 |
2.02 |
1.48 |
2.39 |
2.67 |
1.94 |
1.48 |
2.37 |
2.62 |
2.08 |
1.56 |
2.65 |
2.73 |
2.07 |
1.50 |
2.42 |
3.37 |
2.39 |
1.61 |
2.51 |
3.09 |
2.33 |
1.72 |
3.12 |
3.69 |
2.49 |
1.75 |
2.84 |
3.56 |
2.65 |
1.80 |
2.88 |
3.62 |
2.65 |
1.79 |
3.19 |
| Azithromycin (J01FA10) |
0.62 |
0.48 |
0.38 |
0.65 |
0.83 |
0.59 |
0.45 |
0.74 |
0.87 |
0.66 |
0.53 |
0.86 |
0.93 |
0.76 |
0.60 |
0.97 |
0.97 |
0.72 |
0.54 |
0.81 |
1.12 |
0.80 |
0.56 |
0.83 |
0.99 |
0.74 |
0.57 |
0.92 |
1.03 |
0.73 |
0.54 |
0.81 |
0.98 |
0.76 |
0.56 |
0.84 |
0.99 |
0.76 |
0.56 |
0.86 |
Return to the previous link